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ABSTRACT  
Background: There is little evidence about either prevention or treatment of childhood arterial 
ischaemic stroke (AIS). However drugs that regulate the immune and inflammatory response 
could theoretically prevent occurrence or recurrence of AIS. Additionally, as an acute 
treatment they may limit the neurological damage caused by AIS. Here we systematically 
review the evidence on the use of immunotherapy in childhood AIS. 
Design: A systematic review of publications in databases Embase and Medline from 
inception. All types of evidence were included from trials, cohorts, case-control and cross-
sectional studies, and case reports.  
Results: Thirty-four reports were included: 32 observational studies and two trials. 
Immunotherapy was used in two key patient groups: arteriopathy and acute infection. The 
majority were cases of varicella and primary angiitis of the CNS. All three cohorts and 80% 
of the case studies were treated with steroids. Recurrence rates were low. Analytic studies 
weakly associated steroids with lower odds of new stroke and neurological deficits, and better 
cognitive outcomes in the context of Moyamoya disease and tuberculosis.  
Conclusions: Immunotherapies are used in children with AIS, mainly as steroids for children 
with arteriopathy. However there is currently little robust evidence to either encourage or 
discourage this practice. There is weak evidence consistent with the hypothesis that in certain 
children at-risk, steroids may both reduce the risk of occurrent/recurrent stroke, and enhance 
neurological outcomes. As the potential benefit is still uncertain, this indicates that a trial of 
steroids in childhood AIS may be justified. 
 
 
BACKGROUND 
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Childhood Arterial Ischaemic Stroke (AIS) affects 1.6 per 100,000 children per year in the 
UK.[1] Case fatality is estimated as 9-15%[2-4] and many survivors have neurological or 
functional impairments.[4-6] Estimates of recurrence vary from 1-37%, with the highest rates 
consistently found in children with vascular pathologies.[4 7 8] Currently there is little 
evidence on how to prevent childhood AIS, or how to best to treat it.  
 
Immunotherapy can be defined as the prevention or treatment of disease via substances that 
modulate the body's immune and inflammatory responses.[9] Theoretically immunotherapy 
has a potential for two roles in AIS: firstly to prevent either primary or recurrent AIS, and 
secondly as a potential treatment of AIS which may improve neurological outcomes.  
 
Prevention: 
Many cases of childhood AIS have an immunological/inflammatory aetiology that causes an 
arteriopathy. E.g. primary or latent-reactivated varicella zoster virus (VZV) can lead to 
infection and inflammation of the cerebral arteries, thereby increasing the risk of AIS.[10] 
Other infections such as enterovirus[11], mycoplasma pneumonia[12-14] and herpes 
virus[15] have also been implicated in arteriopathy-related childhood stroke. Recent studies[1 
16] have found arteriopathy in over a third of cases, and earlier studies have had even higher 
estimates.[7 17-20] In cases of arteriopathy, immunotherapy may ameliorate the disease 
process by reducing arterial inflammation. In theory this should reduce the occurrence or 
recurrence of AIS. 
 
Treatment: 
The acute and adaptive inflammatory immune response to ischaemic insult contributes to 
brain tissue damage[21 22] and it was recently demonstrated in a small pilot study that 
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inflammatory markers were elevated in children with AIS compared to controls.[23] This 
implies that pharmacological control of the immune response could help limit this damage, 
and thereby improve outcomes. In animal models, immunotherapy has been associated with 
smaller total infarct size and improved cognitive and functional outcomes.[24-29] In humans, 
steroid trials in the 1970s-80s in adults found little or no evidence of efficacy, and treatment 
was sometimes associated with worse outcome.[30-32] One was a small trial[32] (n=53) 
which found that patients given dexamethasone within 24 hours of cerebral infarction had 
slightly worse outcomes than those given placebo, with lower improvement in neurological 
deficit at 29 days, slightly higher mortality and higher rate of treatment complications 
(mainly infections). However a larger trial[31] (n=113) carried out a decade later by the same 
group found no significant difference in outcome and in fact the dexamethasone group in this 
trial had fractionally lower mortality. A still larger but retrospective study[30] (n=556) 
compared patients given dexamethasone to those given only anti-platelet therapy and glucose. 
Patients receiving dexamethasone had slightly worse outcomes than those who did not, but 
this result is confounded by severity as it was patients who were worse off at baseline who 
were treated with steroids. 
More recently minocycline, a tetracycline antibiotic that modulates the immune response via 
inhibition of T cell migration and microglial activation, has been investigated in adult AIS 
and was associated with improved neurological outcomes.[33] However, inference from adult 
trials is not straightforward as the aetiology of stroke in adults is significantly different to 
children, in whom the predominant risk factors related to lifestyle and old age[34] do not 
apply. If steroids were effective in the population of strokes with an 
immunological/inflammatory aetiology, as is more common in children, this is unlikely to 
have been picked up in adult trials. Although immunotherapies have not been formally 
trialled in childhood AIS specifically, they have been demonstrated to be a safe and effective 
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treatment in children in other inflammatory conditions of the CNS, such as vasculitis and 
lupus.[35-38]  
 
These considerations suggest that immunotherapy could have two potential roles in AIS: 
firstly to prevent either primary or recurrent AIS, and secondly as an acute treatment which 
may improve neurological outcomes. In line with these theoretical considerations, a recent 
survey has shown that there is consensus among experts in the field that the most important 
trial to be done in childhood stroke is an RCT of steroids in AIS.[39]  
 
One complication in considering treatment is that after the active immune response in the 
acute phase of AIS, there follows a generalised immunodepression which leaves patients 
susceptible to infection, significantly increasing morbidity and mortality from stroke in 
adults.[40 41] This has not yet been studied in children, but clearly risk of infection would 
have to be monitored carefully in the context of steroid treatment. A recent systematic review 
of toxicity of short-course oral corticosteroids in children (in a range of diseases) found that 
the rate of major secondary effects was low.[42] The most common adverse effects were 
vomiting, changes in behaviour, and sleep disturbances, with an incidence around or below 
5% of cases. The most serious side effect of treatment was infection, although this occurred 
in less than 1% of cases. 
The current standard treatment in adult acute AIS is thrombolysis. A trial of thrombolysis in 
paediatric stroke, the TIPS trial, has recently been attempted (2012) but was closed early due 
to challenges in recruiting sufficient numbers.[43] One of the key issues is that thrombolysis 
needs to be given in the first 4-5 hours after onset of AIS. Although there is excellent 
recognition of adult stroke enabling prompt treatment, paediatric stoke is often not diagnosed 
until well after this treatment window has passed. A recent study in the UK demonstrated that 
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the median time from symptom onset to diagnosis in childhood AIS was 24 hours (IQR 7-76 
hours).[44] 
 
 
 
METHODS 
We carried out a systematic review of the evidence for the use of immunotherapy in 
childhood AIS. Aims were to elucidate how immunotherapies are being used, and review 
evidence on whether immunotherapy is associated with reduced risk of recurrence, and 
improved neurological outcomes. 
 
Inclusion/Exclusion criteria: 
Types of study included were randomised and non-randomised trials, cohort, case-control and 
cross-sectional studies, case series and case reports. The rationale for such broad inclusion 
criteria is that evidence on this topic was expected to be scarce. 
 
Populations included were children age 30 days to 18 years with AIS confirmed by 
neuroimaging. Children with Haemorrhagic Stroke or Cerebral Venous Sinus Thrombosis 
were excluded as neither of these have a theoretical basis for response to immunotherapy. 
Children with sickle-cell disease were excluded as they comprise a well-delineated sub-
population, in whom much more is known about stroke treatment and prevention. Stroke in 
the context of systemic arteritides such as juvenile systemic lupus erythematosus or Takayasu 
Arteritis was excluded, as these children are likely to be on steroid therapy for their prior 
disease rather than specifically as treatment for stroke. 
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Treatments included were any immunosuppressant (steroid-based or steroid-sparing) given in 
any format, dose and regimen, and whether as a sole or combination therapy. Again the 
rationale is that there was unlikely to be sufficient data on any one type of therapy alone. 
 
Primary outcomes of interest were incidence of recurrent AIS, and general neurological 
recovery (motor, functional, cognitive, behavioural and affective outcomes). Secondary 
outcomes were death, other cerebrovascular events, and other adverse events related to 
treatment. Follow-up periods of any duration were included.  
 
For the purposes of summarising data, outcomes were categorised as: complete recovery; 
mild residual deficits; moderate residual deficits (enough to require daily support); severe 
residual deficits (e.g. quadrepareis, severe cognitive impairment). Categorisation of outcome 
was made on the basis of the description given by the original report authors.  
 
Search and data collection: 
Search strategies were constructed and run on the electronic databases Embase and Medline. 
Search terms were concepts/synonyms for AIS and immunotherapy. A complete search 
strategy is available from the authors. There were no date restrictions. 
 
Search results were exported into the electronic referencing system Endnote X7. Titles and 
abstracts were screened and then full text reviewed for all potentially relevant results. 
References of included studies and reviews were screened for identification of further 
potentially eligible results. 
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A standardised electronic data collection form was used to abstract data. This included study 
type, demographic and clinical data, treatment data, follow-up and outcomes.  
 
Analysis: 
Planned analyses were, as far as data allowed, to examine for the association between 
immunotherapeutic treatment and each outcome of interest. If results allowed we intended 
sub-group analyses by aetiology (suspected infectious/inflammatory, or not), type of 
immunotherapy, dose, duration of therapy, lead time to treatment, and age group.  
 
 
RESULTS 
From 432 initial search results and 83 potential extras from reference lists, 34 reports were 
included (Figure 1). Clarification was sought from authors for reports that potentially 
included overlapping cases,[45-47] and all necessary clarifications were provided.  
  
Of the included results (see online supplement) there were 18 case reports, 10 case series, 
four cohort studies and two RCTs. In some reports only a sub-section of patients were 
relevant. The date range of publications was 1984-2013. Twenty-nine reports gave 
individual-level data and five reports gave group-level data only. The individual-level data 
collectively described 37 children (mean age 8.9 years (sd 4.8), 21/37 (57%) female). The 
group-level data collectively described 115 relevant patients.  
 
Individual data: 
Immunotherapies were used in two main patient groups: vasculitis/arteriopathy; and acute 
infections (Figure 2). The most frequent suspected causes were VZV (13/37, 35%) and 
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childhood Primary Angiitis of the CNS (cPACNS, also called CNS Vasculitis and Isolated 
Angiitis of the CNS) (12/37, 32%). Eight of the 12 cPACNS cases (66%) affected the large-
medium vessels. When combining all cases of arteriopathy together, 30/34 (88%) affected the 
large/medium vessels.  
 
Eleven types of immunotherapy were reported, and more than one immunotherapy was used 
in 16/37 cases (43%).The mean number of immunotherapies used was 1.8. When considering 
all uses of immunotherapies together, 80% were steroids, most commonly prednisone and 
methylprednisolone (Figure 3).  
 
In 13/37 cases (35%) treatment was solely with immunotherapy. In the other cases acyclovir 
(12/37, 32%), aspirin (9/37, 24%), and antibiotics (4/37, 11%) were the most commonly 
reported conjunctive therapies. Antimalarials, antiepileptics, verapamil, Heparin and 
unspecified antithrombotics were reported in ≤3 cases each. In total 15/37 (41%) were 
reportedly treated with some form of antithrombotic (combining those on aspirin, heparin, 
LMWH, and unspecified antithrombotics). It is possible that these and other conjunctive 
therapies were used more frequently, but not reported by the study authors.  
 
Median follow-up time was 12 months (range 3 days to 9 years) although in four cases 
duration of follow-up was not reported. There was only one recurrent stroke (3%) in a case of 
stroke after a severe episode of VZV and vasculitis[48], and two deaths (5%). One death was 
in a case of stroke after persistent VZV infection in the context of AIDS, where the child 
secondarily developed pneumonia[49]. The other death was in the case of a young girl with 
isolated angiitis of the CNS and stroke who had recently started the contraceptive pill[50]. 
17/37 (46%) were described as complete recoveries/asymptomatic at last follow up, 10/37 
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(27%) with mild residual deficits, 5/37 (14%) with moderate, and 2/37 (5%) with severe 
residual deficits. In 1/37 the outcome was not sufficiently reported (Figure 4). Sub-group 
analysis was not appropriate due to the small number of cases, but a breakdown of further 
data on individual cases is given in Appendix A. 
 
  
Group data: 
One cohort was 68 medium-to-large vessel cPACNS cases, including 50 with previous 
AIS,[51] mean age 8.5 years (sd 3.5). As arteriopathies, all of these cases would be at-risk of 
AIS occurrence/recurrence. All were treated with immunotherapy: IV prednisone and 
immunoglobulin acutely, followed by oral prednisone and azathioprine for cases the authors 
categorised as ‘progressive, obliterative’ arteriopathies based on neuroimaging. Follow-up 
was 24 months. There were no recurrent strokes. 2/50 died (4%). General neurological 
outcomes were: 20% complete recovery, 25% minor disabilities, 20% moderate, and 35% 
severe disabilities. Sub-group analysis of neurological outcomes was not given for those with 
and without previous AIS. 
 
Another cohort was 45 cPACNS cases,[45] median age 9.8 years (range 3.3-17.8). 19/45 had 
angiography-positive disease (affecting the large/medium vessels) and 26/45 had 
angiography-negative disease (affecting the small vessels). Treatment was as per institutional 
protocol. For angiography-positive disease, the treatment protocol appeared to be heparin 
plus antiplatelet therapy. It is stated that more recently corticosteroids was added to the 
protocol for this group but it is unclear how many received steroid therapy. For angiography-
negative disease, the treatment protocol appeared to be induction with IV cyclophosphamide 
and prednisone, followed by maintenance therapy with either azathioprine or mycophenolate 
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mofetil. The exact number receiving azathioprine or mycophenolate mofetil or both was not 
clear. Within the whole cohort, 19 cases had evidence of previous probable AIS, 2 of which 
had angiography-negative disease. Median follow-up for the whole cohort was 21.6 months 
(range 3-36 months). There were no reported deaths nor any new or recurrent strokes in any 
of the children in this cPACNS cohort, either in the angiography negative disease group (all 
of whom will have been receiving immunotherapy) or the angiography positive group (an 
undetermined number of whom will have received immunotherapy in the form of steroids in 
addition to heparin and an anti-platelet agent). For the overall cohort, the median Pediatric 
Stroke Outcome Measure (PSOM) score improved from 2.25 at the time of diagnosis to 0.5 at 
12 months, and 0 at 24 months (zero indicating no neurological deficits). The PSOM scores 
were unfortunately not broken down by treatment group or by history of previous AIS.  
 
A cohort of 166 children with bacterial meningitis included 14 presenting with AIS, and 6/14 
treated with immunotherapy (dexamethasone) in addition to antibiotics.[52] The mean age 
was 1.3 years (range 3-36 months). Follow-up was for a minimum of 12 months. There were 
no recurrent strokes. 3/14 (21%) died and 8/14 (57%, including all 6 on immunotherapy) 
were reported as ‘poor outcome’ (including blindness, hydrocephalus, institutionalisation, 
quadriplegia, severe mental retardation and uncontrolled seizures). Outcomes were not 
consistently separated for those on treatment.  Authors felt there was no evidence of the 
effectiveness of dexamethasone, although as it was only given to the most severe/clinically 
deteriorating cases, these results are confounded by severity.  
 
There were two RCTs that while not directly trialling immunotherapy in AIS, did contain 
relevant results. One compared anti-tuberculosis treatment plus prednisone, to anti-
tuberculosis treatment alone in 138 children with Tuberculous Meningitis.[53] 16/68 (24%) 
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in the steroid group and 17/70 (24%) in the non-steroid group presented with AIS. At 6 
months the steroid-treatment group had lower incidence of new stroke (OR 0.67) although 
this was not statistically significant (p=0.14). They also had significantly greater 
improvement in cognitive function (OR 2.19, p=0.038 for IQ>75); and lower mortality (OR 
0.32, p=0.015) compared to controls. Outcome data applied to the whole group so it is not 
clear if the effects are the same in the sub-group with previous stroke.  
 
Another trial compared general anaesthesia (GA) plus nerve block 
(methylprednisolone+bupivacaine) to GA only, in 39 children (mean age 8 years, range 3-13) 
undergoing surgery for Moyamoya disease.[54] Within 24 hours of surgery there was higher 
incidence of new stroke, and neurological deficits in the control group compared to those 
treated with methylprednisolone+bupivacaine (OR 3.2, 95% CI 0.6 to 18.4). The study was 
underpowered to detect a statistically significant difference in outcome, but results are 
suggestive of a protective effect of treatment. The report’s authors speculate that the lower 
incidence of stroke in the treatment group may be related to better pain control and/or more 
stable cerebral blood flow, but it may also be related to the immunomodulating and anti-
inflammatory effect of methylprednisolone.  
 
 
DISCUSSION 
This review was a systematic evaluation of the evidence on the use of immunotherapy in 
childhood AIS. The majority of results were descriptive (case studies, series, cohorts) as 
would be expected for a rare neurological condition. These demonstrate that 
immunotherapies are used in childhood AIS, commonly as steroids in children with 
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arteriopathy. However, with no internal controls or comparison groups they provide very 
weak evidence on the association between treatment and outcomes.  
 
Prevention: 
In previous AIS cohorts, estimates of recurrent stroke have varied from 1%-37%[4 7 8 55]. 
The higher rates of recurrence tend to be found in children with arteriopathies[7]. The cases 
in this review were predominantly arteriopathies, so arguably one might expect to see a high 
rate of recurrence here. However, contrary to this, there was a low rate of recurrence: only 
1/37 (2.7%) in the individual cases, and none in any of the cohorts. 
 
One possible explanation for the low recurrence found in this review is a publication bias. If 
cases with a good outcome were more likely to be written up by clinicians, this could lead to 
an underestimate of recurrence. However, this would not apply to the cohorts. Also 
publication bias may be more likely to go in the other direction: it is commonly the 
complex/severe cases that are written up as case studies, which would if anything lead to an 
overestimate of poor outcomes including recurrence. 
 
The observation of low recurrence in this review is also consistent with, and perhaps 
sympathetic to the theory that the immunotherapy received by these children reduced the risk 
of recurrent AIS. This possibility is supported by the finding in both trials that children 
treated with steroids had reduced odds of recurrent stroke compared to those untreated. The 
key limitation of the trials is that they were underpowered to detect a statistically significant 
difference in recurrence. 
 
Treatment: 
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Broader neurological outcomes in the cases here also appear positive when considered in the 
context of other AIS cohorts: the mortality rate in the cases found here was 5%, whereas the 
best estimate from prospective, population-based studies of childhood AIS is 10%[4]. Other 
cohorts have variously estimated between 4-15% mortality[2 3 56] although the study that 
found the lowest mortality may be vulnerable to sampling bias – as a study of patients in a 
paid-for US healthcare plan, it may under-represent poorer children and thereby 
underestimate poor outcomes. The cohorts in this review reported 0%, 4% and 21% mortality 
respectively, although the latter represented children with stroke in the context of bacterial 
meningitis, who may be expected to have particularly poor outcome. Direct comparisons are 
difficult due to selection biases that affect both systematic reviews, and some of the previous 
studies. However, results are consistent with the theory that immunotherapy has a 
neuroprotective role in treatment of acute AIS due to an inflammatory pathology. This 
possibility is given stronger support from the one trial that was adequately powered to detect 
statistically significant differences, which found that children treated with steroids had 
statistically significantly lower mortality, and improved cognition compared to those 
untreated.[53] The limitation of this trial was that the population was specifically children 
with Tuberculous Meningitis, who although at risk of AIS are not likely to be fully 
representative of AIS. 
 
Overall this review found little robust evidence either in favour or against the use of 
immunotherapy in childhood AIS. There is weak evidence consistent with the hypotheses that 
in certain children at-risk, steroids may reduce the risk of recurrent stroke, and enhance 
neurological outcomes.  
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To our knowledge this is the first systematic review of the role of immunotherapies in 
childhood AIS. A strength of this review is the inclusive search criteria, which should have 
limited the possibility of missing any relevant evidence in an area with very little research so 
far.  
 
A limitation is heterogeneity in the data. Due to the scarcity of the evidence, this review has 
grouped together cases of AIS with different aetiologies, which may be expected to vary in 
both treatment response and overall outcome. Also there may be variations in how clinicians 
classify severity of outcome. Points of homogeneity are that these were almost all cases of 
arteriopathy or acute infection, and mainly treated with steroids. 
Confounding by severity may also be affecting results: if the most severe cases tend to be 
treated with immunotherapy, then the prevalence of poor outcomes in the cases in this review 
will be overestimated. 
The main challenge to interpretation is the scarcity of high-quality, analytic studies, which 
precludes firm conclusions on the efficacy of immunotherapies. 
 
Several points justify further investigation of immunotherapy in childhood AIS. Firstly there 
is good theoretical basis for the hypothesis that immunotherapy could be an effective 
strategy, primarily to prevent recurrence, but also as a treatment in acute stroke to minimise 
neurological damage. Secondly although there is so far no strong positive evidence, the 
findings of this review are compatible with the concept of immunotherapy as an effective 
strategy in some cases. Specifically the findings were sympathetic to the hypothesis that 
steroids may be protective in cases of stroke with an infectious or inflammatory aetiology. 
Thirdly this review demonstrates that children with or at risk of AIS are being treated with 
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immunotherapies, and this practice should either be encouraged or discouraged on the basis 
of better evidence.  
 
There is recent consensus among experts that the most important RCT to be undertaken in the 
field of child stroke is a trial of steroids in AIS.[39] We suggest that as the evidence so far is 
unclear, and as steroids are being used in some cases with uncertain benefit, a trial to 
determine safety and efficacy is justified. The most appropriate target group is likely to be 
children with arteriopathy, as this is the aetiological group most commonly treated in the 
literature and the group with most theoretical chance of benefit. The primary outcome should 
be preventing recurrent AIS, and secondarily measuring the effect on general neurological 
outcomes at a minimum of 12 months. A multicentre collaboration would be crucial to 
achieve sufficient recruitment.  
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What is already known on this topic: 
 Little is known about the prevention or treatment of arterial ischaemic stroke (AIS) in 
children. 
 Theoretically, immunotherapy may reduce the risk of occurrence/recurrence of AIS in 
cases of arteriopathy. It may also help limit neurological damage in acute AIS. 
 Adult trials of steroids in AIS do not give consistent results, and cannot be generalised 
to children. 
 There is expert consensus that the most important trial to be undertaken is an RCT of 
steroids in childhood AIS. 
 
What this study adds: 
 Steroids are used to treat children with AIS, particularly those with an 
infectious/inflammatory aetiology. 
 Although the data is consistent with benefit in some children, so far there is no robust 
evidence on whether or not treatment is associated with better outcomes. 
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 Treatment of childhood AIS should be based on more robust evidence from a 
randomised controlled trial.  
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Figure 1: Flow chart of results included/excluded 
Figure 2: Aetiologies of childhood AIS treated with immunotherapy 
Figure 3: Immunotherapies used in childhood AIS  
Figure 4: Neurological outcomes in immunotherapy-treated childhood AIS  
 
 




Appendix A: Further individual data 
(a) Cases with a presumed infectious/inflammatory aetiology: 
Case 
ID 
Paper Main suspected 
aetiology 
Small/Large 
Vessel 
arteriopathy 
Child age 
(years) 
Gender Immunotherapies used Follow up 
(months) 
Recurrence Outcome / 
Recovery i 
24 Kutlesa 2009 Adenoviral 
infection 
Large 4 M Corticosteroids (unspecified) 1 No Moderate deficits 
(motor) 
1 Abe 2006 CNS Vasculitis Large 12 M Prednisone 36 No Severe residual 
deficits 
31 Salih 2006 Congenital 
toxoplasmosis 
Large 3 days M Prednisolone 58 No NR iii 
7 Bitter 2006 cPACNS Large 5 F IV Cyclophosphamide, IV 
Methylprednisolone, Oral 
Cyclophosphamide, Prednisone 
108 No Complete 
recovery 
30 Rosati 2013 cPACNS Large 6 F Prednisone, Steroids 
(unspecified), Mycophenolate 
6 No Complete 
recovery 
8 Bitter 2006 cPACNS Small 7 F Dexamethasone, IV 
Cyclophosphamide, Prednisone 
14 No Complete 
recovery 
16 Gallagher 
2001 
cPACNS Large 7 F Dexamethasone, Prednisone, IV 
Cyclophosphamide, Azathioprine, 
Methylprednisolone, 
Cyclophosphamide 
12 No Complete 
recovery 
17 Gallagher 
2001 
cPACNS Large 8 F Prednisone, Methylprednisolone, 
IV Cyclophosphamide 
12 No Moderate deficits 
(behavioural) 
15 Gallagher 
2001 
cPACNS Large 11 M Methylprednisolone, Prednisone, 
IV Cyclophosphamide, 
Methotrexate 
21 No Mild deficits 
(motor) 
38 Volcy 2004 cPACNS Large 16 F Steroids (unspecified) NR  No Complete 
recovery 
37 Volcy 2004 cPACNS Large 18 M Steroids (unspecified) NR No Complete 
recovery 
27 Mineyko 
2012 
Focal Cerebral 
Arteriopathy 
Large 14 F IV Methylprednisolone, 
Prednisone, Cyclophosphamide 
18 No Mild deficits 
(functional) 
28 Mineyko 
2012 
Focal Cerebral 
Arteriopathy 
Large 15 M Methylprednisolone, Prednisone 12 No Severe residual 
deficits 
Case 
ID 
Paper Main suspected 
aetiology 
Small/Large 
Vessel 
arteriopathy 
Child age 
(years) 
Gender Immunotherapies used Follow up 
(months) 
Recurrence Outcome / 
Recovery i 
35 Sokol 2000 Henoch-
Schonlein 
purpura 
Small 15 F Corticosteroids (unspecified) NR No Complete 
recovery 
13 Francois 
1996 
HZO Large 4.5 F IV Prednisone 5 NR Mild deficits 
(motor) 
6 Bhat 2002 HZO Large 17 M Steroids (unspecified) 3 No Mild deficits 
29 Nagaratnam 
1987 
Isolated angiitis 
of the CNS 
Large 15 F IV Dexamethasone 3 days No Death 
25 Lanthier 
2001 
Isolated angiitis 
of the CNS 
Small 10 F Prednisone, Cyclophosphamide 72 No Complete 
recovery 
26 Lanthier 
2001 
Isolated angiitis 
of the CNS 
Small 16 F Dexamethasone, Prednisone 8 No Complete 
recovery 
21 Ilia 2011 Pneumococcal 
meningitis with 
vasculitis 
Small 4 F Dexamethasone, 
Methylprednisolone 
2 No Mild deficits 
18 Ganesan 
1997 
VZV Large 8 
months 
F IV Immunoglobulin 0.7 No Complete 
recovery 
36 Tiah 2004 VZV Large 4 M IV Methylprednisolone NR No Complete 
recovery 
14 Frank 1988 VZV Large 4.5 F Dexamethasone 4 NR Death 
2 Alehan 2002 VZV Large 5 F IV Methylprednisolone 12 No Complete 
recovery 
4 Baker 2007 VZV Large 6 M IV Methylprednisolone, oral 
Steroids (unspecified) 
24 No Complete 
recovery 
9 Bodensteiner 
1992 
VZV Large 6 F Prednisone 2 No Mild deficits 
33 Silverstein 
1995 
VZV Large 6 NR Steroids (unspecified) 1 No Mild deficits 
(motor) 
5 Baker 2007 VZV Large 7 F Oral Steroids (unspecified) 2 No Mild deficits 
(motor) 
12 Caruso 2000 VZV Large 7 F IV Methylprednisolone, 
Prednisone 
12 No Complete 
recovery 
Case 
ID 
Paper Main suspected 
aetiology 
Small/Large 
Vessel 
arteriopathy 
Child age 
(years) 
Gender Immunotherapies used Follow up 
(months) 
Recurrence Outcome / 
Recovery i 
32 Shuper 1990 VZV Large 7.5 M IV Methylprednisolone, 
Prednisone 
2 Yes Moderate deficits 
19 Hausler 1997 VZV Large 8 M Prednisolone 5 No Complete 
recovery 
20 Hausler 1997 VZV Large 8 M Prednisolone 14 No Moderate deficits 
(motor) 
34 Singhal 2001 VZV Large 14 M Prednisone 36 No Complete 
recovery 
3 Alexander 
2006 
West Nile Virus Large 9 F IV Methylprednisolone, 
Cyclophosphamide 
24 No Mild deficits 
(motor) 
i. As described by original report authors 
iii. NR = not reported 
 
 
(b) Cases without a presumed infectious/inflammatory aetiology: 
Case 
ID 
Paper Main suspected 
aetiology  
Child age 
(years) 
Gender Immunotherapies used Follow up 
(months) 
Recurrence Outcome 
/Recovery i 
22 Jain 1984 Idiopathic 16 F IV Dexamethasone 6 No Moderate deficits 
(motor) 
11 Byrd 1996 Trauma 5 M Oral Prednisolone 10 No Complete 
recovery 
23 Ko 1990 Trauma 9.5 M IV Dexamethasone 28 No Mild deficits 
(motor) 
i. As described by original report authors 
